Johnson & Johnson Valuation Questioned by Analysts

Johnson & Johnson (NYSE:JNJ) has been attracting attention from investors and analysts due to its valuation. Some are questioning whether the company's stock price is overvalued or undervalued.

The pharmaceutical giant reported strong earnings in recent years, with revenue growing at a steady pace. However, some analysts argue that the company's valuation is not justified by its current financial performance.

Peter Garnry, an investment strategist at Pictet Asset Management, believes that Johnson & Johnson's valuation is currently 'misread' and may be due for a correction. He points out that the stock price has risen significantly over the past year, while earnings have only increased by around 5%.